Franklin Street Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Franklin Street Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-952	Closed	-$121K	–	179
2016 Q4	$121K	Hold	952	–	–	0.02%	164
2016 Q3	$146K	Hold	952	–	–	0.03%	171
2016 Q2	$110K	Hold	952	–	–	0.02%	192
2016 Q1	$108K	Buy	952 +476	+100%	+$72.2K	0.02%	216
2015 Q4	$90K	Buy	476 +238	+100%	+$44.5K	0.02%	218
2015 Q3	$41K	Buy	+238	New	+$85.9K	0.01%	224

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Franklin Street Advisors's VIRX Position: Q1 2017 in Review

Franklin Street Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2017, closing a stake of 952 shares — an estimated $121K sold.

Franklin Street Advisors first reported a position in VIRX in Q3 2015 and held it in 6 quarters. The position peaked at $146K in Q3 2016. 41 funds tracked by Wall St. Rank hold VIRX as of Q1 2017.

Franklin Street Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
Franklin Street Advisors sold 952 Viracta Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $121K.
Franklin Street Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2015 and held it in 6 quarters.
Franklin Street Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $146K in Q3 2016.
41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Franklin Street Advisors's 13F filing for Q1 2017, filed 4 Apr 2017.